926888-15-5

Basic information

• Product Name: (8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester
• Synonyms: (8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester
• CAS NO: 926888-15-5
• Molecular Weight: 399.449
• Mol File: 926888-15-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester(926888-15-5)
• EPA Substance Registry System: (8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester(926888-15-5)

Safety Data

• Hazardous Substances Data: 926888-15-5(Hazardous Substances Data)

Upstream product

• 621-84-1 O-benzyl carbamate 
• 124676-19-3 2-(benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 
• 517874-18-9 (Benzotriazol-1-yl-chlorocarbonyl-methyl)-carbamic acid benzyl ester 
• 4937-62-6 2-amino-4-methylbenzophenone 

Downstream Products

• 155003-12-6 N-((3RS)-1-tert-Butylcarbonylmethyl-2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)urea 
• 1300089-50-2 benzyl (8-methyl-5-phenyl-2-thioxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamate 
• 1300087-14-2 benzyl (1,9-dimethyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)carbamate 
• 924279-56-1 3-amino-8-methyl-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 

Relevant articles and documents

Discovery of epigenetic regulator i-bet762: Lead optimization to afford a clinical candidate inhibitor of the bet bromodomains

The bromo and extra C-terminal domain (BET) family of bromodomains are involved in binding epigenetic marks on histone proteins, more specifically acetylated lysine residues. This paper describes the discovery and structure-activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, and BRD4). This work has yielded a potent, selective compound I-BET762 that is now under evaluation in a phase I/II clinical trial for nuclear protein in testis (NUT) midline carcinoma and other cancers.

CONDENSED AZEPINE DERIVATIVES AS BROMODOMAIN INHIBITORS

Benzodiazepine compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.